Treatment of Schizophrenia and Bipolar Disorder

Introduction to Ziprasidone

Ziprasidone is mentioned as a treatment option for pediatric bipolar disorder by the American Academy of Child and Adolescent Psychiatry, although data is limited 1

Ziprasidone has a unique pharmacological profile, including serotonin-2A (5-HT2A) and dopamine-2 (D2) receptor antagonism, 5-HT1A receptor agonist activity, and weak inhibition of serotonin and norepinephrine reuptake, contributing to its efficacy in treating schizophrenia and bipolar disorder 1

Ziprasidone has a favorable metabolic profile, with no clinically significant weight gain, no adverse effects on cholesterol, triglycerides, or glycemic control, and potential improvements in these parameters when switching from other antipsychotics, making it a suitable option for patients with metabolic concerns 1
Ziprasidone has a low propensity for extrapyramidal side effects, no significant persistent effects on prolactin levels, and is not anticholinergic, but may cause somnolence, according to the National Institute of Neurological Disorders and Stroke 2

Ziprasidone can prolong the QTc interval on ECG, requiring caution in patients with pre-existing cardiac conditions, those taking other medications that prolong QTc, and recommending baseline and periodic ECG monitoring 1
The use of ziprasidone is contraindicated in patients with a history of QT prolongation, recent acute myocardial infarction, uncompensated heart failure, and concurrent use of other QT-prolonging medications, as well as in elderly patients with dementia-related psychosis due to increased mortality risk, as warned by the Food and Drug Administration 1, 2

Ziprasidone must be taken with food (≥500 kcal meal) to ensure proper absorption, with a reduced bioavailability of approximately 60% when taken without food 1, 2
The recommended dose range for ziprasidone is 40-80 mg twice daily, with an initial dose of 20 mg twice daily with food, and titration up to 80 mg twice daily based on clinical response, as recommended by the National Institute of Mental Health and the American Psychiatric Association 2, 1
Regular monitoring of therapeutic response, weight, metabolic parameters, and complete blood count is recommended, especially in patients with pre-existing low WBC or history of drug-induced leukopenia/neutropenia, according to the American Psychiatric Association and the American Diabetes Association 1, 2
Baseline and periodic ECG monitoring for QTc prolongation is recommended, with a reported range of QTc prolongation from 1.7 ms to 30.1 ms, as suggested by the American Heart Association and the American College of Cardiology 2